Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Schering-Plough releases research results

Schering-Plough releases research results

3rd November 2008

Schering-Plough’s interim analysis of a phase II study has revealed that boceprevir in combination with ribarvin and peginterferon improved sustained virologic response (SVR) rates with 28 weeks of therapy.

The combination doubled SVR with 48 weeks of therapy, compared to the current standard of care over the same period in treatment of chronic hepatitis C virus genotype 1.

The study – HCV SPRINT-1 – saw 595 treatment-naive patients with the disease given the treatment, with the results presented at the 59th American Association for the Study of Liver Diseases Annual Meeting.

Attaining SVR 12 or 24 – based on rapid virologic response (RVR) – was greater for boceprevir patients in the lead-in arms compared to the no lead-in arms.

Dr Paul Kwo, Indiana University associate professor of medicine and medical director and lead investigator of the study, said: “The high response rates seen with boceprevir in this study are very exciting, especially given that genotype 1 is the most common and hardest to treat form of hepatitis C.”

Conducted at different sites across Europe, USA and Canada, 77 per cent of the patients were in the USA, with African-Americans accounting for 16 per cent and seven per cent were cirrhotic.

Schering-Plough currently offers medicines in animal health, cardiovascular disease, women’s health and oncology among others.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.